SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB-Reference-Cited by-同舟云学术

SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB

Published:2015-07 Issue:7 Volume:35 Page:1323-1330
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Moisseiev Elad,Katz Gabriel,Moisseiev Joseph,Loewenstein Anat,Goldstein Michaella,Lomnicky Yosef,Abend Yitzhak,Treister Giora,Goldenberg Dafna,Levkovitch-Verbin Hana

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference26 articles.

2. . The Framingham eye study: I. Outline and major prevalence findings.;Kahn;Am J Epidemiol,1977

4. . Ranibizumab for neovascular age-related macular degeneration.;Rosenfeld;N Engl J Med,2006

5. . Ranibizumab versus verteporfin for neovascular age-related macular degeneration.;Brown;N Engl J Med,2006

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravitreal Aflibercept Application in Patients with Type 1 Choroidal Neovascular Membrane Resistant to Ranibizumab Treatment Results;Medical Journal of Western Black Sea;2022-08-31

2. SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB;Retina;2022-05

3. Function-first ligandomics for ocular vascular research and drug target discovery;Experimental Eye Research;2019-05

4. Clinical Changes after Switching from Ranibizumab/Aflibercept to Bevacizumab in Exudative Age-related Macular Degeneration;Journal of the Korean Ophthalmological Society;2019

5. Anti-VEGF treatment switch in neovascular age-related macular degeneration: a comparison of aflibercept versus ranibizumab after a single-dose switch;International Ophthalmology;2018-11-01